LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

LLY

1,018.6

+3.3%↑

JNJ

229.93

+0.53%↑

ABBV

213.62

+1.94%↑

UNH

389.29

-0.09%↓

AZN

184.71

+0.4%↑

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

11.87 0.34

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.4

Massimo

12.01

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.506 49.701
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+67.36% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2.1B
Apertura precedente	11.53
Chiusura precedente	11.87

Notizie sul Sentiment di mercato

By Acuity

10%

90%

8 / 345 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

14.24 / 14.78 Supporto e resistenza

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mag 2026, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19 mag 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19 mag 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 23:28 UTC

Discorsi di Mercato

Utili

F&P Healthcare's Outlook Key for Investors -- Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

19 mag 2026, 23:10 UTC

Discorsi di Mercato

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19 mag 2026, 22:02 UTC

Utili

ZTO Express (Cayman): Di Xu to Resign From Board

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19 mag 2026, 22:01 UTC

Utili

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19 mag 2026, 22:00 UTC

Utili

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19 mag 2026, 21:37 UTC

Utili

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19 mag 2026, 21:31 UTC

Acquisizioni, Fusioni, Takeovers

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19 mag 2026, 21:01 UTC

Utili

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19 mag 2026, 20:58 UTC

Utili

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19 mag 2026, 20:46 UTC

Azioni calde

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19 mag 2026, 20:43 UTC

Discorsi di Mercato

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19 mag 2026, 20:34 UTC

Utili

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q EPS 5c >JHX

19 mag 2026, 20:32 UTC

Utili

James Hardie Industries 4Q Sales $1.4B >JHX

19 mag 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Buy Empower Semiconductor for $1.5B

19 mag 2026, 20:18 UTC

Discorsi di Mercato

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

19 mag 2026, 20:13 UTC

Discorsi di Mercato

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19 mag 2026, 20:03 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19 mag 2026, 20:02 UTC

Acquisizioni, Fusioni, Takeovers

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19 mag 2026, 19:23 UTC

Discorsi di Mercato

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

67.36% in crescita

Previsioni per 12 mesi

Media 20 USD 67.36%

Alto 20 USD

Basso 20 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.24 / 14.78Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

8 / 345 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.